Yossi Biderman « Stock News

mBeach Software Inc. Defining Marketing Strategy for Non-Intrusive Technologies for the Detection of Skin Cancer

Filed under: Press Releases — Tags: diagnostic, early detection, imaging system, mBeach SoftwareInc., MBHS.PK, proprietary, skin cancer, Yossi Biderman — The Editor @ 8:03 pm

TEL AVIV, Israel, - August 23, 2010 (CRWE NEWSWIRE) - mBeach Software Inc. (”MBHS”) (OTCBB:MBHS - News) today issued a stockholder update on its Evolving Marketing Strategy for skin cancer diagnostic solutions. The adopted strategy represents an entrepreneurial concept approach to locating and initiating opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. (”SCS”) to grow the company and become a leading industry player.

The initially targeted countries are the USA, Russia and the CIS, Australia, Germany, Japan, and Israel.

The Basic Strategy concept is a four pillar structure: Preliminary logistics for initiation and maintenance of service for large volume of demand for the device; Advanced survey to define all relevant aspects (Production, Distribution, Tech Support); Survey of the specific targeted regions; Locate and engage a distributor, meeting with the requirements, in the defined country/state/ region.

The marketing strategy in every country will be basically similar and will be executed in similar initial stages. The differences will be the result of health reimbursement programs, Medicare concept, and conduct of distribution and use of medical devices.

mBeach is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.

mBeach CEO Yossi Biderman commented, “The marketing strategy we have defined at this early stage is due to the lengthy regulatory procedures in each country. We expect that the mutual impact of market demand and technical innovative approach on the final product will result in what we think will be a most advanced, adaptable, and technically supported, medical device for the early detection of skin cancer. We expect our SkinScan 650, a non-invasive, point-of-care, doctors’ decision supporting device, to provide the Medical practitioner a much needed user friendly diagnostic solution.”

About SCS

Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.

Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor’s office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. It will help reduce the number of biopsies, lower treatment costs, and improve quality of life.

For more information on SCS, visit www.scs-med.com.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS’ products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Contact:

mBeach Software Inc.
Mr. Yossi Biderman, CEO
+ 972 363535352
info@scs-med.com

******************************************************************

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.

mBeach Software Inc. Targeting Markets for Non-Intrusive Technologies for the Detection of Skin Cancer

Filed under: Press Releases — Tags: mBeach Software Inc., MBHS.PK, skin cancer diagnostic, Yossi Biderman — The Editor @ 8:04 pm

TEL AVIV, Israel, - August 20, 2010 (CRWE NEWSWIRE) - mBeach Software Inc. (”MBHS”) (OTCBB:MBHS - News) today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. (”SCS”) to grow the company and become a leading industry player.

We have identified the Japanese, Hi-Tech orientated market, as a potential pivotal market, with increasing awareness to skin cancer related issues in the past decade.

Total population of Japan exceeds 125 million people, and there is increasing demand for advanced medical technologies.

The number of patients with malignant skin tumors has increased year by year.

The annual increase of deaths from Non Melanoma Skin Cancer (NMSC) is 3.8%. (Hisashi Ohtsukaa, Shogo Nagamatsub).

Early detection is critical to survival, and can lead to almost a one hundred percent cure rate. However, the effectiveness of current cancer detection procedures is heavily dependent on the experience of the examiner, and errors in diagnosis can be fatal. Occasionally, cancers remained undetected, grow further and lead to lower chances of survival. An additional disadvantage with current diagnostic methods is that they rely on a biopsy, the intrusive removal of tissue sample, to confirm the presence of cancerous tissue.

Biopsies can be painful, leave scarring, and often cause unnecessary patient anxiety.

SCS is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.

mBeach CEO Yossi Biderman commented,” The Japanese market and other intended market surveys are being initiated at these early stages due to the lengthy regulatory procedures in each country, before receiving marketing approval. We expect initial approvals to coincide with industrial device following clinical trials, during 2011″.

About SCS

Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.

Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor’s office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. It will help reduce the number of biopsies, lower treatment costs, and improve quality of life.

For more information on SCS, visit www.scs-med.com.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS’ products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Contact:

mBeach Software Inc.
Mr. Yossi Biderman, CEO
+ 972 363535352
info@scs-med.com

******************************************************************

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.

mBeach Software Inc. Targeting New International Market Opportunities

Filed under: Press Releases — Tags: mBeach Software Inc., OTCBB:MBHS, Yossi Biderman — The Editor @ 10:51 pm

TEL AVIV, Israel, - July 30, 2010 (CRWE NEWSWIRE) - mBeach Software Inc. (”MBHS”) (OTCBB:MBHS - News) today announced a strategy of targeting new international market opportunities. In particular, the company has identified the emerging markets of Russia and Commonwealth of Independent States (CIS)

Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.

According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.

mBeach CEO Yossi Biderman commented, “One of the main reasons for relatively high cancer death rates in Russia and CIS is that patients are often diagnosed with the disease once it is too late. This is a very large and growing healthcare market and represents an important opportunity for Skin Cancer Scanning (SCS), our wholly owned subsidiary company. Our simple-to-use, non-invasive, point-of-care, skin cancer detection solution is ideally suited for this market.”

About SCS

Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.

Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor’s office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.

For more information on SCS, visit www.scs-med.com.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS’ products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Contact:

mBeach Software Inc.
Mr. Yossi Biderman, CEO
+ 972 36353532
info@scs-med.com

******************************************************************

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.